BioMarin to pay $840m for GSK castoff

BioMarin Pharmaceutical is to buy rare disease-focused Prosensa for $680m in cash and $160m in contingent milestones if Prosensa's Duchenne muscular dystrophy product – the GSK-reject drisapersen – is approved quickly in the US and Europe.

BioMarin Pharmaceutical is to buy rare disease-focused Prosensa for $680m in cash and $160m in contingent milestones if Prosensa's Duchenne muscular dystrophy product – the GSK-reject drisapersen – is approved quickly in the US and Europe.

Drisapersen had been partnered with GlaxoSmithKline but the big pharma pulled out of the deal following drisapersen's failure in the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Musculoskeletal

More from Therapeutic Category